Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis
18 Dezembro 2023 - 6:01PM
Business Wire
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today
announced it will host a webcast and conference call on Tuesday,
December 19, 2023, at 8:00 a.m. (ET) to provide top-line results
from a Phase 2 clinical trial of ADX‑629 in patients with atopic
dermatitis.
The dial-in numbers are (888) 415-4305 for domestic callers and
(646) 960-0336 for international callers. The access code is
5858366. A live audio webcast of the conference call also will be
accessible from the “Investors & Media” section of Aldeyra's
website at ir.aldeyra.com.
After the live webcast, the event will remain archived on
Aldeyra’s website for 90 days.
About Aldeyra
Aldeyra Therapeutics is a biotechnology company devoted to
discovering innovative therapies designed to treat immune-mediated
diseases. Our approach is to develop pharmaceuticals that modulate
immunological systems, instead of directly inhibiting or activating
single protein targets, with the goal of optimizing multiple
pathways at once while minimizing toxicity. Our product candidates
include RASP (reactive aldehyde species) modulators ADX‑629,
ADX‑246, ADX‑248, and chemically related molecules for the
potential treatment of systemic and retinal immune-mediated
diseases. Our pre-commercial product candidates are reproxalap, a
RASP modulator for the potential treatment of dry eye disease and
allergic conjunctivitis, and ADX-2191, a novel formulation of
intravitreal methotrexate for the potential treatment of
proliferative vitreoretinopathy and retinitis pigmentosa.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231218552145/en/
Investor & Media: David Burke Tel: (917) 618-2651
investorrelations@aldeyra.com
Aldeyra Therapeutics (NASDAQ:ALDX)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Aldeyra Therapeutics (NASDAQ:ALDX)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024